Three-Tesla Magnetic Resonance and Computed Tomography Imaging in Three-Dimensional Conformal Radiotherapy for Localized Prostate Cancer

DOI: 10.4236/ojrad.2011.11001   PDF   HTML     6,107 Downloads   11,602 Views   Citations


Aims and background: we evaluate CT-3Tesla MRI fusion in conformal radiotherapy for localized prostate cancer.Methods: 18 consecutive patients underwent a 3T MRI scan under radiotherapy planning conditions, after the CT scan. Bowel and bladder preparation were prescribed. CT and MR images were automatically fused; prostate and seminal vesicles were contoured on CT and on MRI, organs at risk were defined on CT-MRI fusion. Late rectal and sexual toxicity, differences in target volume between MRI and CT and differences in rectal and penile bulb dose distribution based on CT only or on CT-MRI fusion were evaluated.Results: one patient experienced a late rectal toxicity; no patient had sexual toxicity. The difference between the mean MRI and CT target volumes was statistically significant (p = 0.0001 paired Student's t-test). The dose-volume histogram (DVH) analysis shows a significant reduction of the dose received by the rectum and the penile bulb in MRI-plans compared to CT-plans.Conclusions: 3 Tesla MRI scan under radiotherapy planning conditions along with bowel preparation significantly improves the definition of the target volume sparing normal tissue irradiation.

Share and Cite:

G. Ingrosso, A. Carosi, E. Ponti, P. Bove and R. Santoni, "Three-Tesla Magnetic Resonance and Computed Tomography Imaging in Three-Dimensional Conformal Radiotherapy for Localized Prostate Cancer," Open Journal of Radiology, Vol. 1 No. 1, 2011, pp. 1-8. doi: 10.4236/ojrad.2011.11001.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, M. J. Thun, “Cancer statistics, 2009,” CA: A Cancer Journal for Clinicians, Vol. 59, No. 4, 2009, pp. 225-249.
[2] J. Ferlay, P. Autier, M. Boniol, M. Heanue, M. Colombet, P. Boyle, “Estimates of cancer incidence and mortality in Europe in 2006,” Annals of Oncology, Vol. 18, No. 4, 2007, pp. 581-592.
[3] R. E. Peschel, J. W. Colberg, “Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer,” The Lancet Oncology, Vol. 4, 2003, pp. 233-241.
[4] A. V. D’Amico, R. Whittington, I. Kaplan, et al., “Equiv- alent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml,” International Journal of Radiation Oncology Biology Physics, Vol. 37, 1997, pp. 1053-1058.
[5] A.V. D’Amico, R. Whittington, S. B. Malkowicz, et al., “Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer,” The Journal of the American Medical Association, Vol. 280, 1998, pp. 969-974.
[6] L. Potters, E. A. Klein, M. W. Kattan, et al., “Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation,” Radiotherapy and Oncology, Vol. 71, 2004, pp. 29-33.
[7] A. A. Aizer, J. B. Yu, J. W. Colberg, A. M. McKeon, R. H. Decker, R. E. Peschel, “Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma,” Radiotherapy and Oncology, Vol. 93, No. 2, 2009, pp. 185-191.
[8] S. Welz, M. Nyazi, C. Belka, U. Ganswindt, “Surgery vs. radiotherapy in localized prostate cancer. Which is best?” Radiation Oncology, Vol. 7, No. 3, 2008, pp. 23.
[9] M. J. Zelefsky, Z. Fuks, M. Hunt, et al., “High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients,” International Journal of Radiation Oncology Biology Physics, Vol. 53, No. 5, 2002, pp. 1111-1116.
[10] J. M. Michalski, K. Bae, M. Roach, et al., “Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I / II dose escalation study,” International Journal of Radiation Oncology Biology Physics, Vol. 76, No. 1, 2010, pp. 14-22.
[11] L. Perna, C. Fiorino, C. Cozzarini, et al., “Sparing the penile bulb in the radical irradiation of clinically localised prostate carcinoma: A comparison between MRI and CT prostatic apex definition in 3DCRT, Linac-IMRT and Helical Tomotherapy,” Radiotherapy and Oncology, Vol. 93, No. 1, 2009, pp. 57-63.
[12] A. Villers, L. Lemaitre, J. Haffner, P. Puech, “Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance,” Current Opinion in Urology, Vol. 19, No. 3, 2009, pp. 274-282.
[13] N. Morakkabati-Spitz, P.J. Bastian, J. Gieseke, et al, “MR imaging of the prostate at 3.0T with external phased array coil: preliminary results,” European Journal of Medical Research, Vol. 13, 2008, pp. 287-291. PMid:18558555
[14] M. Roac Radiation Oncology Biology Physics, Vol. 45, No. 4, 1999, pp. 857-865.
[15] C. Rasch, I. Barillot, P. Remeijer, A. Touw, M. van Herk, J. V. Lebesque, “Definition of the prostate in CT and MRI: a multi-observer study,” International Journal of Radiation Oncology Biology Physics, Vol. 43, No. 1, 1999, pp. 57-66.
[16] G. M. Villeirs, K. van Vaerenbergh, L. Vakaet, et al., “Interobserver delineation variation using CT + MRI in intensity-modulated radiotherapy for prostate cancer,” Strahlentherapie und Onkologie, Vol. 181, No. 7, 2005, pp. 424-430.
[17] M. L. Schiebler, M. D. Schnall, H. M. Pollack, et al., “Current role of MR Imaging in the staging of adenocarcinoma of the prostate,” Radiology, Vol. 189, No. 2, 1993, pp. 339-352. PMid:8210358
[18] H. Hricak, S. White, D. Vigneron, et al., “Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils,” Radiology, Vol. 193, No. 3, 1994, pp. 703-709. PMid:7972810
[19] J. J. Futterer, M. R. Engelbrecht, G. J. Jager, et al., “Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils: local staging accuracy of prostate cancer using endorectal coil MR imaging,” Eur- opean Radiology, Vol. 17, 2007, pp. 1055-1065. PMid:1- 7024497
[20] J. E. Husband, A. R. Padhani, A. D. MacVicar, et al., “Magnetic resonance imaging of prostate cancer: Comparison of image quality using endorectal and pelvic phased array coils,” Clinical Radiology, Vol. 53, 1998, pp. 673-681.
[21] Y. Kim, I. C. Hsu, J. Pouliot, et al., “Expandable and rigid endorectal coils for prostate MRI: Impact on pro- state distortion and rigid image registration,” Medical Physics, Vol. 32, 2005, pp. 3569-3578.
[22] S. W. Heijmink, T. W. Scheenen, E. N. Van Lin, A. G. Visser, L. A. Kiemeney, J. A. Witjes, J. O. Barentsz, “Changes in prostate shape and volume and their implications for radiotherapy after introduction of endorectal ballon as determined by MRI at 3T,” International Journal of Radiation Oncology Biology Physics, Vol. 73, No. 5, 2009, pp. 1446-1453.
[23] J. Sosna, I. Pedrosa, W. C. Dewolf, H. Mahallati, R. E. Lenkinski, N. M. Rofsky, “MR imaging of the prostate at 3 Tesla: comparison of an external phased-array coil to imaging with an endorectal coil at 1.5 Tesla,” Academic Radiology, Vol. 11, No. 8, 2004, pp. 857-862.
[24] C. Fiorino, N. Di Muzio, S. Broggi, et al., “Evidence of limited motion of the prostate by carefully emptying the rectum as assessed by daily MVCT image guidance with helical tomotherapy,” International Journal of Radiation Oncology Biology Physics, Vol. 71, No. 2, 2008, pp. 61- 1-617.
[25] M. Stasi, F. Munoz, C. Fiorino, et al., “Emptying the rectum before treatment delivery limits the variations of rectal dose-volume parameters during 3DCRT of prostate cancer,” Radiotherapy and Oncology, Vol. 80, No. 3, 20- 06, pp. 363-370.
[26] R. J. Steenbakkers, K. E. Deurloo, P. J. Nowak, J. V. Lebesque, M. van Herk, C. R. Rasch, “Reduction of the dose delivered to the rectum and bulb of the penis using MRI delineation for radiotherapy of the prostate,” International Journal of Radiation Oncology Biology Physics, Vol. 57, No. 5, 2003, pp. 1269-79.
[27] R. C. Krempien, K. Schubert, D. Zierhut, et al., “Open low-field magnetic resonance imaging in radiation therapy treatment planning,” International Journal of Radiation Oncology Biology Physics, Vol. 53, No. 5, 2002, pp. 1350-1360.
[28] [30] K. E. Wallner, G. S. Merrick, M. L. Benson, W. M. Butler, J. Maki, B. G. Tollenaar, “Penile bulb imaging,” International Journal of Radiation Oncology Biology Physics, Vol. 53, No. 4, 2002, pp. 928-933.
[29] B. M. Fish, B. Pickett, V. Weinberg, et al., “Dose of radiation received by the bulb of the penis correlates with the risk of impotence after three-dimensional conformal radiotherapy for prostate cancer,” Urology, Vol. 57, 2001, pp. 955-959.
[30] G. S. Merrik, K. Wallner, W. M. Butler, et al., “A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction,” International Journal of Radiation Oncology Biology Physics, Vol. 50, 2001, pp. 597-604.
[31] M. Roach 3rd, J. Nam , G. Gagliardi, I. El Naqa, J. O. Deasy, L. B. Marks, “Radiation dose-volume effects and the penile bulb,” International Journal of Radiation Oncology Biology Physics, Vol. 76, No. 3 Suppl, 2010, pp. S130-134.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.